Published in World J Gastroenterol on April 14, 2015
Novel treatment options for portal hypertension. Gastroenterol Rep (Oxf) (2017) 0.75
Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A (1996) 5.94
Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci U S A (1995) 3.53
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med (1993) 3.31
A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med (2005) 1.74
Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology (1998) 1.68
Portal hypertension and its complications. Gastroenterology (2008) 1.50
Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci (2007) 1.44
Chronic thalidomide administration enhances vascular responsiveness to vasopressin in portal-systemic collaterals of bile duct-ligated rats. J Chin Med Assoc (2009) 1.42
Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol (1983) 1.37
Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood (2002) 1.15
Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther (2001) 1.04
Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats. J Hepatol (1996) 1.04
Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology (1996) 1.04
NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol (1999) 1.03
Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice. Behav Brain Res (2007) 0.96
Effects of thalidomide in a mouse model of cerulein-induced acute pancreatitis. Shock (2008) 0.93
Cirrhosis and its complications: evidence based treatment. World J Gastroenterol (2014) 0.93
Current concepts on the role of nitric oxide in portal hypertension. World J Gastroenterol (2013) 0.92
G-protein-coupled receptor kinase interactor-1 (GIT1) is a new endothelial nitric-oxide synthase (eNOS) interactor with functional effects on vascular homeostasis. J Biol Chem (2012) 0.89
The role of nitric oxide synthase isoforms in extrahepatic portal hypertension: studies in gene-knockout mice. Gastroenterology (2003) 0.89
VEGF-induced angiogenesis drives collateral circulation in portal hypertension. J Hepatol (2005) 0.88
Acute haemodynamic responses and inhibition of tumour necrosis factor-alpha by pentoxifylline in rats with cirrhosis. Clin Sci (Lond) (1996) 0.88
Involvement of iNOS-dependent NO production in the stimulation of osteoclast survival by TNF-alpha. Exp Cell Res (2004) 0.88
Effects of tumor necrosis factor, endothelin and nitric oxide on hyperdynamic circulation of rats with acute and chronic portal hypertension. World J Gastroenterol (2004) 0.88
A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. Aliment Pharmacol Ther (2004) 0.87
Tumor necrosis factor-alpha regulates inducible nitric oxide synthase gene expression in the portal hypertensive gastric mucosa of the rat. J Gastrointest Surg (2006) 0.87
Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study. Ann Oncol (2008) 0.87
Effect of tumor necrosis factor-alpha on endothelial and inducible nitric oxide synthase messenger ribonucleic acid expression and nitric oxide synthesis in ischemic and nonischemic isolated rat heart. J Am Coll Cardiol (2003) 0.87
Effects of TNF-alpha on hemodynamic changes and circulating endothelium-derived vasoactive factors in dogs. Am J Physiol (1994) 0.87
Inhibition of hepatic tumour necrosis factor-alpha attenuates the anandamide-induced vasoconstrictive response in cirrhotic rat livers. Liver Int (2009) 0.85
Paraquat poisoning induces TNF-α-dependent iNOS/NO mediated hyporesponsiveness of the aorta to vasoconstrictors in rats. PLoS One (2013) 0.84
Insulin-like growth factor 1 prevents liver injury through the inhibition of TNF-alpha and iNOS induction in D-galactosamine and LPS-treated rats. Shock (2008) 0.84
Tetramethylpyrazine attenuates TNF-α-induced iNOS expression in human endothelial cells: Involvement of Syk-mediated activation of PI3K-IKK-IκB signaling pathways. Exp Cell Res (2013) 0.83
Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. Arch Med Res (2007) 0.83
Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats. Hepatology (2012) 0.83
Circulating microparticles carry a functional endothelial nitric oxide synthase that is decreased in patients with endothelial dysfunction. J Am Heart Assoc (2012) 0.82
Thalidomide decreases intrahepatic resistance in cirrhotic rats. Biochem Biophys Res Commun (2009) 0.82
Inhibition of TNF-alpha improves indomethacin-induced enteropathy in rats by modulating iNOS expression. Dig Dis Sci (2005) 0.81
Clinical manifestations of portal hypertension. Int J Hepatol (2012) 0.81
Thalidomide protects against ischemic neuronal damage induced by focal cerebral ischemia in mice. Neuroscience (2009) 0.81
Endothelial nitric-oxide synthase (eNOS) is activated through G-protein-coupled receptor kinase-interacting protein 1 (GIT1) tyrosine phosphorylation and Src protein. J Biol Chem (2014) 0.81
Thalidomide treatment reduces colon injury induced by experimental colitis. Shock (2005) 0.80
Effect of thalidomide on nitric oxide production in lipopolysaccharide-activated RAW 264.7 cells. J Drugs Dermatol (2010) 0.80
Cicletanine stimulates eNOS phosphorylation and NO production via Akt and MAP kinase/Erk signaling in sinusoidal endothelial cells. Am J Physiol Gastrointest Liver Physiol (2013) 0.80
Protective effect of thalidomide on endotoxin-induced liver injury. Alcohol Clin Exp Res (2003) 0.79
Primary prophylaxis of esophageal variceal bleeding in cirrhosis. Gastroenterol Clin Biol (2008) 0.79
Nitric oxide-dependent and -independent vascular hyporeactivity in mesenteric arteries of portal hypertensive rats. Br J Pharmacol (1997) 0.78
Effect of thalidomide in patients with chronic heart failure. Am Heart J (2002) 0.77
Concentrated grape juice (G8000™) reduces immunoexpression of iNOS, TNF-alpha, COX-2 and DNA damage on 2,4,6-trinitrobenzene sulfonic acid-induced-colitis. Environ Toxicol Pharmacol (2014) 0.77
[Effects of three immunosuppressive agents and simvastatin on cell-proliferation and endothelin secretion of human endothelial cells]. Zhonghua Nei Ke Za Zhi (2008) 0.77
Enhanced potency of perfluorinated thalidomide derivatives for inhibition of LPS-induced tumor necrosis factor-alpha production is associated with a change of mechanism of action. Bioorg Med Chem Lett (1998) 0.76
Variceal hemorrhage: Analysis of 9987 cases from a Japanese nationwide database. Hepatol Res (2014) 0.76
Tumor necrosis factor alpha signaling in the development of experimental murine pre-hepatic portal hypertension. Int J Physiol Pathophysiol Pharmacol (2010) 0.76
Cardiopulmonary effects of tumor necrosis factor-alpha in the piglet: influence of cyclooxygenase inhibition. Biol Neonate (1995) 0.76
[Analysis of nitrites/nitrates (NOx) in serum]. Biomed Khim (2004) 0.76
Portal hypertension: cytokines and endothelins. Hepatogastroenterology (1999) 0.76
Potential mechanisms of benefit with thalidomide in chronic heart failure. Am J Cardiovasc Drugs (2007) 0.76